The FDA "will not be happy on the cardiovascular [CV] front, short of the data from a study designed specifically to address that issue" with regard to testosterone replacement therapy (TRT), Clarus Therapeutics Inc. CEO Robert Dudley told BioWorld Today, and the agency has asked vendors of marketed products to take on such work.